KRYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Krystal Biotech Inc (KRYS) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment with multiple price target increases, and significant institutional interest suggest a solid growth trajectory. While technical indicators are neutral, the overall sentiment and fundamentals support a buy decision.
The MACD histogram is -1.077, below 0, and negatively contracting, indicating a lack of upward momentum. RSI is neutral at 55.418, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 274.726, R1: 292.181, S1: 257.272, R2: 302.964, S2: 246.488. Overall, technical indicators are neutral.
Multiple analysts have raised price targets significantly, with the highest target at $371, citing strong Vyjuvek sales, pipeline progress, and growth potential in new markets.
Institutional investor Redmile Group increased its stake in Krystal Biotech, signaling confidence in the company's prospects.
Financial performance in Q4 2025 showed revenue growth of 17.52% YoY and net income growth of 13.02% YoY.
Gross margin dropped slightly by -0.76% YoY, which could indicate rising costs.
Technical indicators are neutral, providing no immediate bullish signals.
In Q4 2025, revenue increased by 17.52% YoY to $107.1 million, net income rose by 13.02% YoY to $51.4 million, and EPS grew by 11.84% YoY to $1.7. However, gross margin dropped slightly to 93.85%, down -0.76% YoY.
Analysts are overwhelmingly positive on Krystal Biotech, with multiple firms raising price targets significantly. Guggenheim, Chardan, Citi, Jefferies, Goldman Sachs, Clear Street, BofA, and TD Cowen have all reiterated Buy ratings, citing strong Vyjuvek sales, pipeline progress, and growth potential in new markets. The highest price target is $371.
